Cancer: general and other | Guidance and guideline topic | NICE

Everything NICE has produced on the topic of cancer: general and other. Includes any related guidance, NICE Pathways, quality standards and advice.

10 new

and

0 updated

products since January 2017.

NICE Pathways - mapping our guidance

Quality standards

Cancer services for children and young people (QS55) February 2014
Suspected cancer (QS124) June 2016

Interventional procedures guidance

Cytoreduction surgery followed by hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (IPG331) February 2010
Endoscopic radical inguinal lymphadenectomy (IPG398) June 2011

Technology appraisal guidance

Diagnostics guidance

Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16) December 2014

NICE Guidelines

Improving outcomes in children and young people with cancer (CSG7) August 2005
Improving outcomes in urological cancers (CSG2) September 2002
Improving supportive and palliative care for adults with cancer (CSG4) March 2004
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104) July 2010
Suspected cancer: recognition and referral (NG12) June 2015

In development

Cabozantinib and vandetanib for treating unresectable locally advanced or metastatic medullary thyroid cancer [ID56] (GID-TA10082) January 2018 Technology appraisal guidance
End of life care for adults in the last year of life: service delivery (GID-CGWAVE0799) July 2018 NICE guidelines
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059] (GID-TA10101) March 2018 Technology appraisal guidance
Neuroblastoma (high risk) - APN311 [ID910] (GID-TA10069) March 2018 Technology appraisal guidance
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799] (GID-TAG507) TBC Technology appraisal guidance
Neuroendocrine tumours (metastatic, unresectable, progressive) - 177 Lu-dotatate [ID1224] (GID-TA10167) December 2017 Technology appraisal guidance
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma [ID972] (GID-TA10100) July 2017 Technology appraisal guidance
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184] (GID-TA10168) May 2018 Technology appraisal guidance
Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415] (GID-TAG431) TBC Technology appraisal guidance